96 completed, 18 active not recruiting, 18 unknown, 5 recruiting. 149 Phase 3, 12 Phase 2.
Follow Papillomavirus Infections: new trials by email Literature Review of Papillomavirus Infections trials Research Report on Papillomavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children Zopapogene imadenovec-drba - Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis | Phase 3 | Not yet recruiting | Precigen, Inc | 15 | 2026-12-31 | 2026-10-28 |
| A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108) V503, Placebo - Papillomavirus Infections | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 930 | 2026-10-10 | 2026-10-22 |
| Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts Intralesional Acyclovir, Intralesional Zinc Sulphate - Warts, Plantar Warts | Phase 3 | Not yet recruiting | Assiut University | 76 | 2026-10-01 | 2026-09-29 |
| Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster - Human Papillomavirus (HPV) Infection | Phase 3 | Not yet recruiting | PT Bio Farma | 266 | 2026-10-01 | 2026-09-17 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan) - Common Warts, Common Warts (Verruca Vulgaris) | Phase 3 | Recruiting | Verrica Pharmaceuticals Inc. | 300 | 2026-06-15 | 2026-09-03 |
| Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) Cantharidin - Common Warts (Verruca Vulgaris), Common Warts | Phase 3 | Recruiting | Verrica Pharmaceuticals Inc. | 250 | 2026-03-11 | 2026-10-22 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) VP-102, Vehicle - Common Warts, Common Warts (Verruca Vulgaris) | Phase 3 | Active not recruiting | Verrica Pharmaceuticals Inc. | 302 | 2025-12-17 | 2026-10-23 |
| Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) - Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma | Phase 3 | Active not recruiting | National Vaccine and Serum Institute, China | 1800 | 2025-11-21 | 2026-01-23 |
| PREVENT HPV -Related Cancers Trial PREVENT - HPV Vaccination, Uptake Vaccination | Phase 3 | Active not recruiting | University of Utah | 1455 | 2025-10-06 | 2026-10-29 |
| Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen - Human Papillomavirus Infection | Phase 3 | Active not recruiting | Serum Institute of India Pvt. Ltd. | 450 | 2025-10-03 | 2026-06-29 |
| A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli), Aluminum Adjuvant - Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia | Phase 3 | Active not recruiting | Xiamen University | 9300 | 2025-04-11 | 2025-07-31 |
| Candin for the Treatment of Common Warts Candin, Intradermal Solution, Placebo - Common Warts (Verruca Vulgaris) | Phase 3 | Completed | Nielsen BioSciences, Inc. | 330 | 2025-01-22 | 2025-09-05 |
| Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient Injection of protein purified derivative - Anogenital Warts, HIV Infection | Phase 2 / Phase 3 | Unknown | Universitas Padjadjaran | 30 | 2024-09-15 | 2024-09-19 |
| A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Genital Wart, Penile Cancer | Phase 3 | Active not recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 9000 | 2024-07-11 | 2024-12-12 |
| Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline - Warts | Phase 2 / Phase 3 | Recruiting | Western Institute for Veterans Research | 120 | 2024-03-25 | 2024-04-05 |
| A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine Nonavalent HPV study vaccine, GARDASIL® 9 - Human Papillomavirus Infection | Phase 3 | Unknown | Beijing Health Guard Biotechnology, Inc | 1260 | 2023-11-21 | 2024-01-23 |
| Cold Atmospheric Plasma Device Extension Study Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP) - Verruca Vulgaris, Molluscum Contagiosum | Phase 3 | Terminated | Medical University of South Carolina | 60 | 2023-09-18 | 2026-04-03 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）, placebo - HPV InfectioN, HPV-Related Carcinoma | Phase 3 | Active not recruiting | Sinocelltech Ltd. | 18000 | 2023-08-13 | 2023-09-18 |
| Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial HPV vaccine, HPV testing, HAV vaccine - HPV Infection | Phase 3 | Not yet recruiting | International Agency for Research on Cancer | 8000 | 2023-02-01 | 2022-08-03 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
Showing 20 of 149. Sign in to see all of them.
Uterine Cervical Neoplasms (43) · Condylomata Acuminata (42) · Warts (18) · Vaginal Neoplasms (12) · Vulvar Neoplasms (11) · Anus Neoplasms (7) · HIV Infections (6) · Uterine Cervical Dysplasia (6) · Infections (5) · Meningitis (2) · Precancerous Conditions (2) · Recurrence (2) · Squamous Intraepithelial Lesions (2) · Tetanus (2)
DNA Virus Infections (149) · Tumor Virus Infections (149) · Virus Diseases (147) · Infections (144) · Communicable Diseases (133) · Disease Attributes (133) · Genital Diseases (133) · Pathologic Processes (133) · Pathological Conditions, Signs and Symptoms (133) · Sexually Transmitted Diseases, Viral (133) · Urogenital Diseases (133) · Sexually Transmitted Diseases (132) · Skin Diseases (60) · Skin Diseases, Infectious (60) · Skin and Connective Tissue Diseases (60)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (26) · human papillomavirus vaccine, L1 type 16, 18 (23) · Papillomavirus Vaccines (11) · Vaccines, Synthetic (11) · Vaccines (8) · Blood Specimen Collection (4) · Imiquimod (3) · Tuberculin (3) · 2-Propanol (2) · Duration of Therapy (2) · Engerix-B (2) · Hepatitis A Vaccines (2) · Light Coagulation (2) · Measles-Mumps-Rubella Vaccine (2) · N-phenylacetoaminomethylene-DL-p-nitrophenylalanine (2)
GlaxoSmithKline (41) · Merck Sharp & Dohme LLC (36) · Shanghai Bovax Biotechnology Co., Ltd. (7) · Assiut University (5) · Xiamen University (4) · Aclaris Therapeutics, Inc. (3) · Beijing Health Guard Biotechnology, Inc (3) · Verrica Pharmaceuticals Inc. (3) · AIDS Malignancy Consortium (2) · Assistance Publique - Hôpitaux de Paris (2) · Graceway Pharmaceuticals, LLC (2) · International Agency for Research on Cancer (2) · National Vaccine and Serum Institute, China (2) · Shanghai Zerun Biotechnology Co.,Ltd (2) · CHU de Quebec-Universite Laval (1)
United States (30) · China (28) · Canada (13) · Germany (13) · Taiwan (9) · Colombia (7) · Italy (7) · Japan (7) · Mexico (7) · Belgium (6) · Brazil (6) · France (6) · Netherlands (6) · Spain (6) · Thailand (6)
Jun Zhang, master (3) · Ting Huang (3) · Jason Wu, MD (2) · Yongjiang Liu, Bachelor (2) · Adelaide A Hebert, MD (1) · Ajay Rangaraj, MD, MSc (1) · Alex Mutombo Baleka, MD (1) · Alice Lytwyn, MD, FRCPC (1) · Andy M. Trotti, MD (1) · Ann-Marie Wennberg, MD, PhD (1) · Armando Baena, MSc, PhD (1) · Binti Sany Salina, Doctor (1)
PMID 41276263, PMID 27422279, PMID 19935017, PMID 32184277, PMID 19236277, PMID 19236279, PMID 25424785, PMID 29074187, PMID 29211620, PMID 30982556, PMID 31824976, PMID 35149535, PMID 41166720, PMID 20949623, PMID 21471141, PMID 22265115, PMID 22454089, PMID 23066159, PMID 23299013, PMID 24731816, PMID 29269325, PMID 29767739, PMID 29995724, PMID 34939897, PMID 11238198, PMID 12807939, PMID 15897380, PMID 16973081, PMID 17602732, PMID 18164106, PMID 18515521, PMID 18532873, PMID 19116707, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19453788, PMID 19493565, PMID 19505910, PMID 19586656, PMID 19616720, PMID 19652630, PMID 19936044, PMID 20113920, PMID 20189491, PMID 20197322, PMID 20370481, PMID 20413076, PMID 20647284, PMID 21216000
2009 (3), 2017 (3), 2004 (2), 2005 (2), 2008 (2), U01CA121947 (2), 2014 (1), 2019 (1), R01CA279973 (1), U54CA242639 (1), UM1CA121947 (1)